Anifrolumab Placebo
Sponsors
AstraZeneca AB, Astrazeneca AB
Conditions
Active Proliferative Lupus NephritisAutoimmune diseasesImmune system diseasesInterstitial lung disease (ILD)Polymyositis or dermatomyositis according to 2017 EULAR / ACR classification criteriaSystemic Sclerosis (SSc) presenting with Limited or Diffuse Cutaneous Subsets
Phase 3
A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis
Active, not recruitingCTIS2023-505976-31-00
Start: 2023-11-24Target: 112Updated: 2025-10-20
A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis
Active, not recruitingCTIS2023-506359-68-00
Start: 2022-04-08Target: 69Updated: 2025-05-15
A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
RecruitingCTIS2023-504022-19-01
Start: 2024-12-13Target: 84Updated: 2026-01-23